Collaboration Between TriLink BioTechnologies and Alphazyme
TriLink BioTechnologies and Alphazyme, two companies under the Maravai LifeSciences umbrella, have combined their expertise to launch CleanScribe RNA Polymerase. This groundbreaking enzyme is crafted to dramatically lower levels of double-stranded RNA (dsRNA) during mRNA production. By cutting dsRNA by as much as 85%, the aim is to streamline the development of safer and more effective mRNA-based therapeutics.
What You Need to Know About CleanScribe RNA Polymerase
CleanScribe RNA Polymerase operates as a DNA-dependent RNA polymerase, facilitating in vitro transcription (IVT) of recombinant genes that are regulated by the T7 promoter. In conventional IVT processes, dsRNA can be produced as a byproduct, leading to harmful inflammatory reactions in host cells. The CleanScribe polymerase is specifically designed to reduce the formation of dsRNA when compared to the traditional wild-type T7 RNA Polymerase.
The Role of High-Quality Enzymes in mRNA Production
In today’s rapidly changing world of mRNA medicine, keeping a well-functioning supply chain is essential for drug developers. Justin Barbosa, VP and General Manager of TriLink Discovery, points out that the integration of top-notch IVT enzymes, mRNA capping analogs, and modified nucleotides is crucial for effective mRNA manufacturing. The CleanScribe RNA Polymerase is meticulously crafted to give researchers a dependable way to lower dsRNA levels without sacrificing other important quality aspects of mRNA.
CleanScribe RNA Polymerase: Key Advantages and Uses
The CleanScribe RNA Polymerase provides researchers with a powerful tool for minimizing dsRNA in their IVT reactions. It is particularly suited for uses such as mRNA synthesis, saRNA synthesis, the preparation of radiolabeled RNA probes, and the development of RNA constructs for future research. Its easy integration into current IVT procedures means no significant modifications are necessary, making it versatile for a wide array of research applications.
Perspectives from Industry Professionals
Chad Decker, VP and General Manager at Alphazyme, shares his thoughts on the partnership: “We’re thrilled to collaborate with TriLink on CleanScribe RNA Polymerase. High-quality mRNA therapeutics depend largely on superior raw materials, so we see exciting potential for this IVT enzyme in the industry.”
Additional Offerings by TriLink BioTechnologies
In addition to CleanScribe RNA Polymerase, TriLink offers a comprehensive range of products, including mRNA capping analogs like the renowned CleanCap technology, essential mRNA raw materials, and various IVT enzymes, such as the wild-type T7 RNA polymerase. With over 25 years of specialized experience in nucleic acids, TriLink is dedicated to propelling the areas of therapeutics, vaccines, and diagnostics through exceptional technology and chemistry, complemented by their CDMO services.
Dedication to Quality and Progress
As part of Maravai LifeSciences, TriLink BioTechnologies aims to be a leading name in nucleic acid and mRNA solutions globally. The company takes pride in providing high-quality materials and services to important players, including pharmaceutical firms and pioneering biotechs. The CleanScribe initiative exemplifies their ongoing dedication to addressing the evolving demands of the biotechnology field.
Frequently Asked Questions
What is CleanScribe RNA Polymerase?
CleanScribe RNA Polymerase is a cutting-edge enzyme created by TriLink BioTechnologies and Alphazyme, designed to significantly lower double-stranded RNA levels in mRNA production.
How does CleanScribe enhance mRNA therapeutics?
This enzyme cuts down dsRNA formation by as much as 85%, thereby boosting the safety and effectiveness of mRNA-based therapies.
Which companies are involved in the collaboration?
TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have come together for this innovative product launch.
What are the uses of CleanScribe RNA Polymerase?
This enzyme is valuable in mRNA synthesis, saRNA synthesis, and the preparation of radiolabeled RNA probes, among other applications.
Why is it essential to reduce dsRNA in mRNA production?
Lowering dsRNA is critical since it can cause unwanted inflammatory responses during the application of mRNA therapeutics, which helps improve safety profiles.
